By Lucas Project Foundation
Read Alex TLC’s original update
Progress in research can begin with a conversation and a question worth exploring. A recent update from Alex, The Leukodystrophy Charity (Alex TLC), offers a look at that early work.
On November 6, 2026, Alex TLC reported that its chief executive, Sara Hunt, had visited an adrenoleukodystrophy (ALD) drug-repurposing project at the MRC Laboratory of Medical Sciences. Researchers are using worm models to study the disease. November 6 is the announcement date; the update does not give the visit’s exact date.
Why study worms?
Drug repurposing means investigating whether an existing medicine could have another use. The laboratory’s research description explains how its team uses small roundworms called C. elegans to model rare genetic diseases and measure responses to drugs.
That description explains the laboratory’s general approach. It does not establish which medicines might work for ALD.
How the community helped connect the work
Alex TLC says its Community Weekend Science Day helped connect this early research with LeukoLabs, leukodystrophy specialists and the Inherited White Matter Disorders Service. Its update thanks André Brown, Joe McElvaney and their team for sharing the project.
This is a concrete example of a family-support organization helping people exchange research ideas.
What families can take from this update
The announcement describes an early-stage project, not a clinical trial result. It provides no drug names, measured ALD outcomes or evidence of benefit in people. A response in a worm model would not, by itself, establish safety or effectiveness for a person with ALD.
There is room to welcome the collaboration and remain clear about what is still unknown. For now, this is research to follow—not a reason to change treatment.